Latest "Evrogen Joint Stock Company." News Stories

16:18 EST 22nd January 2019 | BioPortfolio

Here are the most relevant search results for "Evrogen Joint Stock Company." found in our extensive news archives from over 250 global news sources.

More Information about Evrogen Joint Stock Company. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Evrogen Joint Stock Company. for you to read. Along with our medical data and news we also list Evrogen Joint Stock Company. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Evrogen Joint Stock Company. Companies for you to search.

Showing "Evrogen Joint Stock Company" News Articles 1–25 of 22,000+

Tuesday 22nd January 2019

Transcat Announces Third Quarter Fiscal Year 2019 Conference Call and Webcast

Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it will release its third quarter fiscal year 2019 results after the...

Hanger Announces Date of 2018 Fourth Quarter and Full Year Earnings Release and Conference Call

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2018 after the market closes on Thursday, March 14, 2019. Hanger's management team will host a conference call with the financial ...

Revance Announces Closing of Public Offering of Common Stock

Gross Proceeds of Offering Total 115.0 Million Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the closing of an underwritten public offering of 6,764,705 shares of its common stock...

SDP/SI Introduces a New Flexible Coupling Equipped with Vibration Damping Technology

Integrally Molded Vibration-Resistant Rubber Damps Vibration While Maintaining Torsional Rigidity HICKSVILLE, New York (PRWEB) January 22, 2019 Stock Drive Products/Sterling Instrument (SDP/SI), a leader in providing mechanical based design, engineering, and precision manufacturing services for critical motion control and small power transmission applications has introduced several new series of ...

FDA Places Clinical Hold on Translate Bio’s IND for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company has received verbal notification from the U.S. Food and Drug Administration (FDA) that the …

BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2019

BIOQUAL, Inc. (OTC Pink: BIOQ) (     Six Months EndedNovember 30, Three Months EndedNov...

Hemp Leader Charlotte's Web Holdings Inc May Be a Potential Marijuana Giant in 2019

Charlotte's Web Holdings Stock Forecast Charlotte's Web Holdings Inc (OTCMKTS:CWBHF, CNSX:CWEB) may just be the best hemp stock you've never heard of. Thanks to industrialized hemp being legalized ...

Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy

Rocket Pharmaceuticals (Nasdaq: RCKT) a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-A501. As quoted in the press release: “This acceptance marks the first Rocket-sponsored IND cleared for our AAV platform and the third for our … Cont...

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the … Continued The post MediciNov...

Acquisition Opportunity – the leading “bio” life-science portal is seeking new ownership

22 January 2019 Dorchester, UK:  The founder of BioPortfolio Limited Peter Barfoot launched today a Private Memorandum outlining the opportunity to acquire the leading “bio” life-science portal and associated research report store The acquisition of the BioPortfolio websites will provide the purchaser with a vehic...

Data Published in Lancet Oncology from Lilly’s Phase 3 Trial Shows Improvement in Overall Survival with Cyramza in Second-Line AFP-High HCC Patients

INDIANAPOLIS, Jan. 18, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people with AFP-High (alpha-fetoprotein ≥400 ng/mL) hepatocellular carcinoma (HCC) were published online today in The Lancet Oncology. Data fr...

LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is give...

Jaguar Health, Inc.: Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale

SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ('Jaguar' or the 'Company'), a commercial stage pharmaceutical company focused on developing novel, sustainabl...

VetStem Biopharma is Pleased to Announce Dr. Douglas Stramel of Advanced Care Veterinary Services is Successfully Using the Pall V-PET™ Platelet Therapy System

Dr. Douglas Stramel of Advanced Care Veterinary Services has been using Veterinary Platelet Enhancement Therapy (V-PET™) since 2016. Pinky, a Great Dane with a torn cruciate ligament, is among his patients who have had a favorable response to the therapy. POWAY, Calif. (PRWEB) January 22, 2019 Dr. Douglas Stramel of Advanced Care Veterinary Services in Carrollton, Texas has been using the Pall...

Maryland Attorney General’s Lead Poisoning Lawsuit Cites Company’s ‘Outrageous Abuse Of Younger Adults’

The lawsuit details how Access Funding pressured victims, many of whom were mentally impaired, with calls and texts offering quick cash. News on lead poisoning comes out of Ohio, also.

DionyMed Brands Inc. Signs Binding Term Sheet to Acquire Massachusetts’ Pioneer Valley Extracts, LLC

DionyMed Enters Massachusetts Market with Award-Winning Brands DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME), a multi-state cannabis brands, distribution and delivery platform, today announced it has signed a binding term sheet to acquire P

Harvest Health & Recreation Inc. Now Trading on OTCQX

Harvest Upgrades to OTCQX Best Market for Better Investor Visibility Harvest Health & Recreation Inc. (CSE: HARV) (

Surmodics to Webcast First Quarter Fiscal 2019 Earnings Conference Call on January 30

Webcast is Live at 4 p.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2019 conference call on Wednesday, January 30, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news...

Eppendorf 5415 D Centrifuge

C $199.30 (0 Bids)End Date: Monday Jan-28-2019 21:55:09 ESTBid now | Add to watch list Biotech365 : Eppendorf 5415 D Centrifuge BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool or a Bioinformatic software to … Continue reading →

Allscripts to release fourth-quarter and full-year 2018 financial results February 21

CHICAGO, Jan. 22, 2019 (GLOBE NEWSWIRE) — Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months and full year ended December 31, 2018, after the close of stock market hours on Thursday, February 21, 2019. … Continue reading →

Rutgers researchers discover cause of bone loss in people with joint replacements

Rutgers researchers have discovered the long-sought reason that many people with joint replacements experience harmful inflammation and bone loss.

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel and selective JAK1 inhibitor, in combination with corticoste...

Tenet Announces Private Offering of Senior Secured Notes to Refinance $768 Million in Outstanding Notes

Tenet Healthcare Corporation (NYSE: THC) intends to refinance $768 million of its currently outstanding notes by offering to sell $750 million of newly issued notes through a private placement. The offering consists of $750 million in aggregate principal amount of newly issued senior secured second lien notes due 2027 issued by Tenet (the “notes”). ...

Tilray® to Acquire Natura Naturals Holdings Inc. for up to C$70 Million Subject to Performance Milestones

Acquisition increases the Company’s capacity to supply branded cannabis products Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ:TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced it has entered into a definitive agreement (“the Agreement”) pursuant to which Tilray, through a wholly-own...

Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease

- Phase 1 Clinical Trial to Commence in the Second Quarter of 2019 - Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-A501. RP-A501 is the ...

Quick Search


News Quicklinks